FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients

International Journal of Biological Markers

Volumn 30, Issue 1, 2015, Pages e88-e95

  Chang, Chia Chu ^a   Lin, Hung Hsin ^b,c   Lin, Jen Kou ^b,c   Lin, Chun Chi ^b,c   Lan, Yuan Tzu ^b,c   Wang, Huann Sheng ^b,c   Yang, Shung Haur ^b,c   Chen, Wei Shone ^b,c   Lin, Tzu Chen ^b   Jiang, Jeng Kai ^b,c   Chang, Shih Ching ^b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; FBXW7; Overall survival; Tumor suppressor gene

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; DNA EXTRACTION; FBXW7 GENE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ADULT; COLORECTAL TUMOR; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; F-BOX PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 84930066039     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000125     Document Type: Article

References (45)

1. Cancer registry annual report (2010). Taiwan, ROC: The Department of Health, The Executive Yuan; 2013.
2. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008; 8(2): 83-93.
3. Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012; 31(1-2): 75-87.
4. Kemp Z, Rowan A, Chambers W, et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 2005; 65(24): 11361-11366.
5. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007; 67(19): 9006-9012.
6. Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013; 108(11): 1785-1793.
7. Grim JE. Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models. Gut. 2014; 63(5): 707-709.
8. Reed SI. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol. 2003; 4(11): 855-864.
9. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005; 8(1): 25-33.
10. Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004; 303(5662): 1374-1378.
11. Rajagopalan H, Jallepalli PV, Rago C, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature. 2004; 428(6978): 77-81.
12. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001; 294(5540): 173-177.
13. Yada M, Hatakeyama S, Kamura T, et al. Phosphorylationdependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23(10): 2116-2125.
14. Gupta-Rossi N, Le Bail O, Gonen H, et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem. 2001; 276(37): 34371-34378.
15. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem. 2001; 276(38): 35847-35853.
16. Mao JH, Perez-Losada J, Wu D, et al. Fbxw7/Cdc4 is a p53 dependent, haploinsufficient tumour suppressor gene. Nature. 2004; 432(7018): 775-779.
17. Kwon YW, Kim IJ, Wu D, et al. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res. 2012; 10(6): 834-844.
18. Fujii Y, Yada M, Nishiyama M, et al. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitindependent degradation. Cancer Sci. 2006; 97(8): 729-736.
19. Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010; 70(11): 4728-4738.
20. Liu N, Li H, Li S, et al. The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem. 2010; 285(24): 18858-18867.
21. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471(7336): 110-114.
22. Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011; 471(7336): 104-109.
23. Punga T, Bengoechea-Alonso MT, Ericsson J. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem. 2006; 281(35): 25278-25286.
24. Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF (Fbw7). Cell Metab. 2005; 1(6): 379-391.
25. Esquejo RM, Jeon TI, Osborne TF. Lipid-cell cycle nexus: SREBP regulates microRNAs targeting Fbxw7. Cell Cycle. 2014; 13(3): 339-340.
26. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008; 321(5895): 1499-1502.
27. Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009; 69(23): 8967-8976.
28. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-1474.
29. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7): 979-994.
30. Lin CC, Lai YL, Lin TC, et al. Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis. 2012; 27(3): 277-286.
31. Chang SC, Lin JK, Yang SH, et al. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006; 118: 1721-1727.
32. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsat ellite instability in colorectal cancer. Cancer Res. 1998; 58(22): 5248-5257.
33. Cancer Genome Atlas N; Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.
34. Lee JW, Soung YH, Kim HJ, et al. Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer. 2006; 42(14): 2369-2373.
35. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006; 5(1): 78-83.
36. Hubalek MM, Widschwendter A, Erdel M, et al. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene. 2004; 23(23): 4187-4192.
37. Jardim DL, Wheler JJ, Hess K, et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS ONE. 2014; 9(2): e89388.
38. Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol. 2007; 8(7): 651-657.
39. Lan YT, Yang SH, Chang SC, et al. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis. 2012; 27: 657-663.
40. Hari DM, Leung AM, Lee JH, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg. 2013; 217: 181-190.
41. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008; 61(5): 561-569.
42. Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol. 2010; 101(5): 396-400.
43. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene. 2005; 24(17): 2776-2786.
44. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62(16): 4535-4539.
45. Milne AN, Leguit R, Corver WE, et al. Loss of CDC4/FBXW7 in gastric carcinoma. Cell Oncol. 2010; 32: 347-359.